ProteoGenix is a leading antibody engineering company with services that have successfully helped develop three therapeutic antibodies and 30+ more in clinical and preclinical trials. Our complete one-stop antibody engineering services safeguard your investment with strict go-no-go guarantees. The best part? We do all the work and you take all the credit. You retain the intellectual property of each engineered antibody we create. With over 25 years of antibody engineering experience, you can trust us to consistently deliver superior antibodies that perform in the clinic or the lab. Give us a call today and see how easy it is to accelerate your antibody engineering project.
Monoclonal Antibody Humanization
Bispecific Antibody Development
Antibody Affinity Maturation
Antibody Developability Services
The Most Complete Antibody Engineering Toolbox
We cover all the engineering technologies needed to develop therapeutic and diagnostic antibodies, so you can work with a single partner.
25+ Years of Experience in Antibody Engineering
Unmatched expertise honed over 25+ years ensures precision and effectiveness, delivering exceptional results for targeted therapies.
Safe Investment (Includes Go/ No Go Guarantees)
Our go/ no go checkpoints minimize your risk and maximize success in antibody engineering development.
You possess complete ownership of the modified antibodies generated.
One-Stop Solution: One Company from Discovery to Production
A streamlined process with one expert company ensures seamless coordination, faster progress, and the most optimal outcome for you.
Continuous communication empowers consumers, providing transparency, reassurance, and personalized guidance throughout the antibody engineering journey.
Established in 2003, ProteoGenix initially focused on developing diagnostic assays and biotherapeutics to identify novel proteins. However, specializing in protein assays naturally requires the development of custom antibodies for protein diagnostic assays.
Realizing the significance of both superior antibodies and proteins, ProteoGenix expanded to become an antibody engineering company, enabling clinical access, and emerged as a leader in the antibody production space.
At ProteoGenix, our ambition is to be an extension of your research team, providing you with fresh expertise and a collaborative approach. The following are the three steps ProteoGenix leverages to integrate with your existing team.
You share your specifications, and our experts propose a comprehensive strategy, including go-no-go checkpoints and guarantees, saving you time and resources.
If the initial project shows promising results, we continue to progress hand in hand. In case of any hurdles, we offer alternative strategies or decide to discontinue if necessary.
If, after an initial engineering phase, you decide to proceed further, we seamlessly transition into production.
Throughout our 20+ years of experience, we have diligently worked to understand our customers and their expectations, enabling us to craft bespoke offers tailored to your specific needs. We take pride in anticipating future biomolecule demands and designing proactive development strategies to fulfill those needs efficiently.
ProteoGenix’s diverse portfolio comprises six interrelated service areas, each brimming with innovative solutions. As your trusted partner, we are committed to delivering excellence and driving success in every stage of your journey, from the earliest discovery to the final clinical stages.
At ProteoGenix, our antibody engineering services offer a range of pricing options to suit diverse needs. Depending on the specific requirements, the cost can vary from a few hundred euros for conjugation of HRP (Horseradish Peroxidase) to several thousand euros for complex engineering processes like antibody humanization of bispecific antibody development.
When considering whether to proceed with an engineering stage, practical advice becomes crucial. While undertaking a developability stage incurs significant costs, it can lead to substantial savings during large-scale production. This initial investment ensures the selection of the most promising candidates, reducing potential risks and optimizing the overall efficiency of the production process.
Affinity maturation, another critical engineering process, can dramatically impact antibody performance. By increasing the antibody’s affinity by a factor of 5 to 1000, this process enhances its potency, potentially leading to improved therapeutic outcomes. Investing in affinity maturation can be a game-changer for the success of the antibody in clinical applications.
At ProteoGenix, we work closely with our clients to assess their specific needs and budget constraints, tailoring our antibody engineering services accordingly. Our expert team provides detailed cost estimates and advises on the most suitable engineering steps to achieve the desired goals effectively and efficiently. Whether you’re seeking minor optimizations or substantial improvements in antibody performance, our flexible pricing and personalized approach ensure the best possible outcomes for your research and development endeavors.
Antibody engineering is the process of modifying customized antibodies.
Our antibody experts use advanced techniques to manipulate the genes responsible for producing antibodies, allowing them to specifically target certain diseases or molecules.
Our antibody engineering services offer diverse ways to transform a suboptimal antibody with modest antigen affinity and the propensity to aggregate into a supercharged drug-conjugated antibody that binds the target antigen. Our one-stop suite of antibody engineering services ensures that we can engineer your antibodies from discovery to pre-clinical trials. Below are descriptions of each antibody engineering service we offer at ProteoGenix.
Antibody humanization is the process of modifying antibodies derived from non-human sources, such as mice, to make them more similar to human antibodies.
This is important for developing antibody-based therapeutics because fully humanized antibodies are less likely to trigger negative immune reactions in patients, increasing their safety and effectiveness.
By humanizing antibodies, scientists can retain the antibody’s specificity and affinity for its target while reducing the risk of adverse reactions. This allows for the development of more successful treatments for various diseases, improving patient outcomes in the field of therapeutics.
Learn more about our monoclonal antibody humanization service.
A bispecific antibody is an engineered antibody that can simultaneously bind to two different targets. This unique characteristic allows it to bring two different molecules or cells together, leading to various therapeutic benefits.
Bispecific antibodies are important in human therapeutics as they can precisely target specific cells or molecules involved in diseases, such as cancer. They exert their therapeutic effects by:
Bispecific antibodies offer a versatile approach for improved treatment outcomes by enhancing specificity, efficacy, and therapeutic options for various diseases.
Learn more about our bispecific antibody development services.
ProteoGenix’s bioconjugation service involves linking or attaching different molecules to antibodies, such as proteins or drugs, to create a bioconjugate.
This process enables the development of targeted drug delivery systems, diagnostic tools, and therapeutic agents. In human therapeutics, bioconjugation plays a crucial role as it allows for the precise and controlled delivery of drugs to specific sites in the body, increasing their efficacy while minimizing side effects.
Bioconjugation also enables the development of diagnostic methods that can accurately detect diseases or biomarkers. We are a leading antibody engineering company that specializes in two different bioconjugation services, antibody-drug conjugation, and antibody labeling.
An antibody-drug conjugate (ADC) is a specialized type of bioconjugate that combines an antibody with a potent therapeutic drug. The antibody component recognizes and binds to specific target molecules found on diseased cells, while the attached drug payload delivers a powerful therapeutic effect, such as inhibiting cell growth or inducing cell death.
ADCs have potential therapeutic uses in various diseases, particularly cancer. They can selectively deliver cytotoxic drugs to tumor cells, minimizing damage to healthy cells and improving treatment efficacy. ADCs offer a targeted approach to precision medicine, enhancing the therapeutic index and reducing side effects.
Learn more about our antibody-drug conjugation services.
Antibody labeling involves attaching a detectable marker or reporter molecule to an antibody, allowing for visualization or detection of specific molecules or cells.
This labeling technique is vital in diagnostic and therapeutic applications. Labeled antibodies enable accurate detection of disease markers, aiding in the diagnosis of various conditions. They can also be used in imaging techniques to visualize specific targets, such as tumor cells.
Learn how affordable our antibody labeling services are.
Antibody developability services refer to a range of scientific evaluations and assessments performed on antibody candidates during the development process.
These services focus on determining the suitability, safety, and efficacy of an antibody as a potential therapeutic. They include assessing factors such as stability, aggregation propensity, manufacturability, immunogenicity, and pharmacokinetics. Antibody developability services are vital because they help identify potential issues early on and guide the optimization and selection of lead antibody candidates.
By addressing developability concerns, these services increase the chances of successfully developing safe and effective therapeutic antibodies, streamlining the drug development process, and minimizing the risk of failures in later stages of development.
Learn how we can improve the biophysical characteristic of your antibody to accelerate market entry using our antibody developability services.
ProteoGenix’s antibody affinity maturation service involves the optimization of antibody affinity, which is the strength of binding between an antibody and its target molecule. These services aim to enhance the antibody’s ability to specifically recognize and bind to its target with higher affinity.
ProteoGenix has a high-performing series of approaches designed to generate antibodies with improved binding properties. This process is crucial in therapeutic development because higher affinity antibodies can exhibit enhanced therapeutic efficacy by increasing target engagement and potency. ProeoGenix also optimizes for:
Learn how ProteoGenix and supercharge your antibodies affinity using our antibody affinity maturation service.
Antibody engineering plays a pivotal role in improving various characteristics of antibodies for therapeutic purposes. For instance, engineering can enhance tumor penetration by modifying the antibody’s structure, allowing better access to tumor cells and improving treatment efficacy.
In addition, rapid clearance from the body can be achieved by engineering antibodies with properties that facilitate their efficient elimination, reducing potential side effects and enabling repeated dosing. Furthermore, lower kidney uptake can be achieved by modifying the antibody’s properties to minimize accumulation in the kidneys, thereby reducing the risk of renal toxicity.
Furthermore, specific formats such as antibody-drug conjugates (ADCs) or bispecific antibodies can be engineered to leverage unique mechanisms of action, enabling targeted drug delivery or simultaneous binding to multiple targets, expanding the therapeutic potential of antibodies.
Antibody engineering plays a crucial role in improving the diagnostic characteristics of antibodies. Through engineering techniques, antibodies can be optimized for various diagnostic assays such as Western blot, flow cytometry, immunofluorescence, ELISA, and more.
By modifying their specificity and affinity, engineering can enhance antibody performance in detecting and quantifying specific molecules or cells in a sample. Antibodies can be engineered to have higher sensitivity, enabling the detection of low-abundance targets. Furthermore, engineering can improve the selectivity of antibodies, reducing cross-reactivity with non-target molecules, thereby increasing the accuracy and reliability of diagnostic results. Additionally, antibody engineering facilitates the conjugation of fluorescent or enzyme labels, enabling their use in fluorescence-based or enzyme-linked assays, and expanding the capabilities of antibody-based diagnostics.
Got a question or need a quote? Message us and we'll get back to you 48 hours or less.
Your cart is currently empty.